Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-GCA: upadacitinib in giant cell arteritis
MOH_2022-02-10_010602Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in giant cell arteritis (GCA) (3 arms), sponsored by AbbVie Inc. Started Jan 2022; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on MOH_2022-02-10_010602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-10_010602.